PMC:4277126 / 89283-90104 JSONTXT

{"project":"2_test","denotations":[{"id":"25552899-21293326-26094364","span":{"begin":269,"end":272},"obj":"21293326"},{"id":"25552899-15519360-26094365","span":{"begin":369,"end":372},"obj":"15519360"},{"id":"25552899-15519360-26094366","span":{"begin":630,"end":633},"obj":"15519360"}],"text":"Hypolipidemic effects\nBased on data from the 2005–2008 National Health and Nutrition Examination Survey, an estimated 71 million (33.5%) US adults aged ≥20 years had high LDL-C, but only 34 million (48.1%) were treated and 23 million (33.2%) had their LDL-C controlled.117 Control of high LDL-C can reduce cardiovascular morbidity and mortality substantially. Luo et al107 investigated the hypolipidemic effect of LBPs on alloxan-induced hyperlipidemic rabbits. LBPs significantly reduced serum total cholesterol and triglyceride concentrations and markedly increased HDL-C levels after treatment with LBPs for 10 days in rabbits.107 LBPs also showed potent antioxidant activities in hyperlipidemic rabbits. These data demonstrate that the hypolipidemic effect of LBPs and anti-oxidation should contribute to this effect."}